These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 20570888)
1. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Tomihari M; Chung JS; Akiyoshi H; Cruz PD; Ariizumi K Cancer Res; 2010 Jul; 70(14):5778-87. PubMed ID: 20570888 [TBL] [Abstract][Full Text] [Related]
2. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. Chung JS; Dougherty I; Cruz PD; Ariizumi K J Immunol; 2007 Nov; 179(9):5778-84. PubMed ID: 17947650 [TBL] [Abstract][Full Text] [Related]
3. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Chung JS; Bonkobara M; Tomihari M; Cruz PD; Ariizumi K Eur J Immunol; 2009 Apr; 39(4):965-74. PubMed ID: 19350579 [TBL] [Abstract][Full Text] [Related]
4. DC-HIL is a negative regulator of T lymphocyte activation. Chung JS; Sato K; Dougherty II; Cruz PD; Ariizumi K Blood; 2007 May; 109(10):4320-7. PubMed ID: 17284525 [TBL] [Abstract][Full Text] [Related]
5. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499 [TBL] [Abstract][Full Text] [Related]
9. Melanoma-Derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-Lymphocytes from the Pre-Metastatic Niches. Ramani V; Teshima T; Tamura K; Chung JS; Kobayashi M; Cruz PD; Ariizumi K J Invest Dermatol; 2018 Nov; 138(11):2443-2451. PubMed ID: 29857071 [TBL] [Abstract][Full Text] [Related]
10. Binding of DC-HIL to dermatophytic fungi induces tyrosine phosphorylation and potentiates antigen presenting cell function. Chung JS; Yudate T; Tomihari M; Akiyoshi H; Cruz PD; Ariizumi K J Immunol; 2009 Oct; 183(8):5190-8. PubMed ID: 19794069 [TBL] [Abstract][Full Text] [Related]
11. The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease. Chung JS; Tomihari M; Tamura K; Kojima T; Cruz PD; Ariizumi K Immunology; 2013 Feb; 138(2):173-82. PubMed ID: 23113638 [TBL] [Abstract][Full Text] [Related]
12. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749 [TBL] [Abstract][Full Text] [Related]
13. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Chung JS; Shiue LH; Duvic M; Pandya A; Cruz PD; Ariizumi K Blood; 2011 Mar; 117(12):3382-90. PubMed ID: 21252093 [TBL] [Abstract][Full Text] [Related]
15. High intensity focused ultrasound enhances anti-tumor immunity by inhibiting the negative regulatory effect of miR-134 on CD86 in a murine melanoma model. Yuan SM; Li H; Yang M; Zha H; Sun H; Li XR; Li AF; Gu Y; Duan L; Luo JY; Li CY; Wang Y; Wang ZB; He TC; Zhou L Oncotarget; 2015 Nov; 6(35):37626-37. PubMed ID: 26485753 [TBL] [Abstract][Full Text] [Related]
16. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835 [TBL] [Abstract][Full Text] [Related]
17. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096 [TBL] [Abstract][Full Text] [Related]
18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
19. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491 [TBL] [Abstract][Full Text] [Related]
20. INAM plays a critical role in IFN-γ production by NK cells interacting with polyinosinic-polycytidylic acid-stimulated accessory cells. Kasamatsu J; Azuma M; Oshiumi H; Morioka Y; Okabe M; Ebihara T; Matsumoto M; Seya T J Immunol; 2014 Nov; 193(10):5199-207. PubMed ID: 25320282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]